NO974695L - Farmasöytisk preparat inneholdende benzimidazol for inhibering av vekst av cancer - Google Patents

Farmasöytisk preparat inneholdende benzimidazol for inhibering av vekst av cancer

Info

Publication number
NO974695L
NO974695L NO974695A NO974695A NO974695L NO 974695 L NO974695 L NO 974695L NO 974695 A NO974695 A NO 974695A NO 974695 A NO974695 A NO 974695A NO 974695 L NO974695 L NO 974695L
Authority
NO
Norway
Prior art keywords
hydrogen
carbon atoms
pharmaceutical preparation
less
preparation containing
Prior art date
Application number
NO974695A
Other languages
English (en)
Other versions
NO974695D0 (no
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO974695D0 publication Critical patent/NO974695D0/no
Publication of NO974695L publication Critical patent/NO974695L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Farmasøytisk preparat for behandling av leukemi i pattedyr er omtalt. Det spesielle fungicid som anvendes er et benzimidazol-derivat med formel I hvor X er hydrogen, halogen, alkyl med mindre enn 7 karbonatomer eller alkoksy med mindre enn 7 karbonatomer, n er et positivt helt tall som er mindre enn 4, Y er hydrogen, klor, nitro, metyl eller etyl, og R er hydrogen eller en alkylgruppe med fra l til 8 karbonatomer, og R2 er 4-tiazolyl eller NHCOORj^ hvor Rx er et alifatisk hydrokarbon med mindre enn 7 karbonatomer, eller farmasøytisk tålbare uorganiske eller organiske syre- addisjonssalter derav. Et farmasøytisk preparat som inhiberer veksten av tumorer og cancere i pattedyr og som kan anvendes for å behandle virusinfeksjoner som omfatter et fungicid i kombinasjon med kjemoterapeutiske midler er angitt. Det spesielle fungicid som anvendes er et benzimidazol-derivat. Potensatorer kan også være inkludert i preparatet.
NO974695A 1995-04-12 1997-10-10 Farmasöytisk preparat inneholdende benzimidazol for inhibering av vekst av cancer NO974695L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42091495A 1995-04-12 1995-04-12
US47381795A 1995-06-07 1995-06-07
US183795P 1995-08-03 1995-08-03
PCT/US1996/004955 WO1996032107A1 (en) 1995-04-12 1996-04-11 A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
NO974695D0 NO974695D0 (no) 1997-10-10
NO974695L true NO974695L (no) 1997-12-08

Family

ID=27357012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974695A NO974695L (no) 1995-04-12 1997-10-10 Farmasöytisk preparat inneholdende benzimidazol for inhibering av vekst av cancer

Country Status (19)

Country Link
EP (1) EP0821586B1 (no)
JP (2) JPH11503459A (no)
KR (1) KR19980703828A (no)
CN (1) CN1181010A (no)
AT (1) ATE242634T1 (no)
AU (1) AU714078B2 (no)
BR (1) BR9604974A (no)
CA (1) CA2217952C (no)
CZ (1) CZ323497A3 (no)
DE (1) DE69628645T2 (no)
HU (1) HUP9801532A3 (no)
IL (1) IL117875A0 (no)
NO (1) NO974695L (no)
NZ (1) NZ305784A (no)
PL (1) PL322733A1 (no)
SK (1) SK138497A3 (no)
TR (2) TR199701147T1 (no)
TW (1) TW427887B (no)
WO (1) WO1996032107A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) * 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
AU763272B2 (en) * 1997-05-16 2003-07-17 Uaf Technologies And Research Llc Benzimidazole-2-carbamates for the treatment of viral infections and cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
KR101092132B1 (ko) * 1998-11-09 2011-12-12 바이오겐 아이덱 인크. 키메라 항-cd20항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
JP2005521712A (ja) 2002-03-26 2005-07-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 弱塩基の可溶化
KR20070095921A (ko) 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 조갑 단위의 상태를 치료하기 위한 조성물 및 방법
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
CN103450093A (zh) * 2013-09-06 2013-12-18 中国药科大学 2-苄氨基苯并咪唑类化合物及其用途
CN108383797B (zh) * 2018-03-09 2020-07-21 浙江农林大学 一种防腐化合物及其制备方法与应用
KR102342313B1 (ko) * 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance

Also Published As

Publication number Publication date
TW427887B (en) 2001-04-01
DE69628645D1 (de) 2003-07-17
WO1996032107A1 (en) 1996-10-17
KR19980703828A (ko) 1998-12-05
CN1181010A (zh) 1998-05-06
EP0821586A1 (en) 1998-02-04
EP0821586B1 (en) 2003-06-11
NZ305784A (en) 2001-03-30
NO974695D0 (no) 1997-10-10
CA2217952A1 (en) 1996-10-17
HUP9801532A2 (hu) 1999-01-28
AU5389796A (en) 1996-10-30
DE69628645T2 (de) 2004-05-13
CA2217952C (en) 2002-06-25
AU714078B2 (en) 1999-12-16
ATE242634T1 (de) 2003-06-15
JPH11503459A (ja) 1999-03-26
TR199701147T1 (xx) 1998-02-21
IL117875A0 (en) 1996-08-04
PL322733A1 (en) 1998-02-16
SK138497A3 (en) 1998-05-06
HUP9801532A3 (en) 1999-05-28
TR199801562T2 (xx) 1998-10-21
CZ323497A3 (cs) 1998-03-18
JP2007284446A (ja) 2007-11-01
BR9604974A (pt) 1998-06-09

Similar Documents

Publication Publication Date Title
NO974695L (no) Farmasöytisk preparat inneholdende benzimidazol for inhibering av vekst av cancer
MX9707809A (es) Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
TR199901528T2 (xx) Viral enfeksiyonlar ve kanser tedavisinde benzimidazol-2-karbamatlar�n kullan�m�.
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BG103947A (en) Derivatives of 9-oxymerythromycin
PA8486401A1 (es) Antibioticos cetolidos carbamato y carbazato
NO975660L (no) Anvendelse av benzimidazoler for fremstilling av et medikament for behandling av leukemi
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
KR910016915A (ko) 과콜레스테롤혈증 치료제
IS5588A (is) Æxliseyðandi miðlar
ES2118945T3 (es) Derivados de melamina utilizados en el tratamiento del cancer.
BG104933A (en) Water soluble azoles and broad-spectrum antifungals
NO982998L (no) Synergistisk anti-mikrobielle blandinger inneholdende 1-hydroksymetylpyrazol og et konserveringsmiddel
IE883515L (en) N-(23-vinblastinoyl) derivatives of 1-aminomethyl-phosphonic¹acid
DE59108566D1 (de) Heteroarylmethylbenzole-Aromatasehemmer
EA200200292A1 (ru) Производные гигромицина
SE8800863L (sv) 3-(2-haloalkyl)-1,4-oxatiiner och 2-(2-haloalkyl)1,4-ditiiner och bahandling av leukemi och tumoerer daermed
AU8083401A (en) Biologically active macrolides, compositions, and uses thereof
MX9709833A (es) Uso de benzimidazoles para la fabricacion de un medicamento para el tratamiento de leucemia.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application